Trajectory of enthesitis over time in patients with enthesitis at baseline
tofacitinib-treated, enthesitis
ENTHESITIS, ENTHESITIS
Regardless of baseline location or severity, the proportion of patients with enthesitis (LEI > 0 or SPARCC > 0) generally decreased over time with tofacitinib treatment (Fig. Enthesitis presences/relapse of resolved enthesitis (patients with LEI > 0/SPARCC > 0 at baseline). *Indicates a comparison where the 95% CI for tofacitinib does not overlap with the 95% CI for placebo. At month 6, the proportions of tofacitinib-treated patients with enthesitis assessed by LEI were reduced by 40–50% across baseline locations (Fig. For patients with LEI > 0 at baseline whose enthesitis had resolved (LEI = 0) at month 1, 26.3%, 15.6%, and 30.8% of patients treated with tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo, respectively, had relapsed at month 3 (Fig. At month 3, for patients with SPARCC > 0 at baseline who had resolved enthesitis (SPARCC = 0) at month 1, 45.5%, 17.4%, and 41.2% of patients treated with tofacitinib 5 mg BID, tofacitinib 10 mg BID, and placebo, respectively, had relapsed (Fig. 